A. Muntean

Neoadjuvant conformal chemoradiation with induction chemotherapy for rectal adenocarcinoma. A prospective observational study.

Z. Fekete, V. Nagy, L. Resiga, 2014, Journal of gastrointestinal and liver diseases : JGLD.

What is the significance of a microscopically positive resection margin in the curative-intent treatment of rectal adenocarcinoma? A retrospective study.

Z. Fekete, V. Nagy, L. Resiga, 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Y. Bang, Z. Wainberg, J. Taieb, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Y. Bang, Keun-Wook Lee, C. Yen, 2018 .

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.

Y. Bang, Z. Wainberg, Keun-Wook Lee, 2019, Future oncology.

Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Y. Bang, J. Taieb, M. Dvorkin, 2020 .

Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.

Y. Bang, F. Ciardiello, L. Wyrwicz, 2016 .